Business Wire

MD-ENVIVA

Share
European Parliament Continues to Recognize Primary Woody Biomass as a Renewable Energy Source

Today, the European Parliament once again voted to recognize primary woody biomass as a renewable energy source. This is consistent with its prior classification under both the first Renewable Energy Directive (RED) and RED II. Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, welcomes the designation as it marks a critical step in the right direction toward more low-carbon, drop-in alternatives to fossil fuels for power and heat generation, as part of an all-in renewables strategy to reduce carbon emissions and limit global dependence on fossil fuels.

Primary woody biomass is an essential renewable energy source for meeting the ambition sought by the EU Parliament to increase renewable energy to 45 percent by 2030, and for achieving the EU’s goal of carbon neutrality by 2050. In the words of Markus Pieper, the Member of Parliament leading on RED III, at the press conference held following the results of the plenary, “We do need wood-based biomass as a source of energy if we genuinely are to undertake this energy transition.”

The Parliament’s vote this week brings its position considerably closer to those of the Council and EU Commission by recognizing primary woody biomass as renewable, ensuring its continued zero-carbon rating in the EU Emissions Trading Scheme, and allowing its use to increase in volume.

“One thing is clear: wood-based biomass is a building block of the energy transition and, despite the vote of left-green Members of the European Parliament, can still be counted as renewable energy. The new directive will set the necessary framework to achieve the greatest possible CO2 reduction effect and not to ensure that our forests are burned in the future. I am counting on the member states to follow our proposals as the procedure progresses (“trilogue”),” continued Mr. Pieper in his statement.

The Council and EU Commission have continued their steadfast support for primary woody biomass and for its increased utilization to deliver climate change benefits and security of energy supply. Today’s vote serves as an initial negotiating position in the European Union’s process. After this vote, the EU Parliament, the Council of the EU, and the EU Commission will begin trilogue discussions, which are negotiations among the three parties, that are estimated to reach a final compromise on RED III in the first half of 2023.

“Heading into trilogues, the EU Parliament brought its position one step closer towards the mainstream views of the Council and the Commission, and away from the earlier minority position taken by the ENVI committee.

“While the process is foreign to those of us in the U.S., as an Austrian native, I can appreciate the complex nature of the EU legislative process, and that a compromise needs to be reached in trilogue negotiations to address the energy transition, security, and affordability crisis facing the EU. Today, biomass accounts for almost 60 percent of renewable energy in Europe.

“All serious pathways for achieving climate neutrality show that the use of bioenergy must and can be increased sustainably. The EU Commission’s own impact assessment for RED III outlines a need to increase bioenergy use from 2030 to 2050 by an average of 69 percent to provide vital grid balancing services, high temperature heat for industry, advanced biofuels, and negative emissions,” said Thomas Meth, President of Enviva.

“A failure to increase woody biomass use in the EU would mean failure in meeting climate goals, increased cost to EU consumers, and further disruption to security of energy supply on the brink of winter, when bioenergy makes up 25 percent of European heating supply and when incremental investments in more woody biomass infrastructure are desperately needed. At Enviva, we are encouraged by the progress made and are confident that a pragmatic and reasonable outcome will be reached,” concluded Meth.

About Enviva

Enviva Inc. (NYSE: EVA) is the world’s largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets. Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi, and is constructing its 11th plant in Epes, Alabama. Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with creditworthy customers in the United Kingdom, the European Union, and Japan, helping to accelerate the energy transition and to decarbonize hard-to-abate sectors like steel, cement, lime, chemicals, and aviation fuels. Enviva exports its wood pellets to global markets through its deep-water marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party deep-water marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.

To learn more about Enviva, please visit our website at www.envivabiomass.com. Follow Enviva on social media @Enviva.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005763/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye